Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NPB8
UPID:
GPCP1_HUMAN
Alternative names:
Glycerophosphodiester phosphodiesterase 5
Alternative UPACC:
Q9NPB8; D3DW06; Q9BQL8; Q9NUX0
Background:
Glycerophosphocholine phosphodiesterase GPCPD1, also known as Glycerophosphodiester phosphodiesterase 5, plays a crucial role in the negative regulation of skeletal muscle differentiation. This function is independent of its glycerophosphocholine phosphodiesterase activity, highlighting its multifaceted role in cellular processes.
Therapeutic significance:
Understanding the role of Glycerophosphocholine phosphodiesterase GPCPD1 could open doors to potential therapeutic strategies. Its unique function in muscle differentiation positions it as a key target for developing treatments aimed at muscle-related diseases.